Clinical Genetic and Metabolism Department, National Children's Hospital, CCSS, San José, Costa Rica.
Research Unit, Hospital San Juan de Dios, CCSS, San José, Costa Rica.
Orphanet J Rare Dis. 2022 Jan 10;17(1):13. doi: 10.1186/s13023-021-02162-z.
Commonly known as Batten disease, the neuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of rare pediatric lysosomal storage disorders characterized by the intracellular accumulation of autofluorescent material (known as lipofuscin), progressive neurodegeneration, and neurological symptoms. In 2002, a disease-causing NCL mutation in the CLN6 gene was identified (c.214G > T) in the Costa Rican population, but the frequency of this mutation among local Batten disease patients remains incompletely characterized, as do clinical and demographic attributes for this rare patient population.
To describe the main sociodemographic and clinical characteristics of patients with a clinical diagnosis for Batten Disease treated at the National Children's Hospital in Costa Rica and to characterize via molecular testing their causative mutations.
DNA extracted from buccal swabs was used for CLN6 gene sequencing. Participants' sociodemographic and clinical characteristics were also obtained from their medical records.
Nine patients with a clinical diagnosis of Batten disease were identified. Genetic sequencing determined the presence of the previously described Costa Rican homozygous mutation in 8 of 9 cases. One patient did not have mutations in the CLN6 gene. In all cases where the Costa Rican CLN6 mutation was present, it was accompanied by a substitution in intron 2. Patients were born in 4 of the 7 Costa Rican provinces, with an average onset of symptoms close to 4 years of age. No parental consanguinity was present in pedigrees. Initial clinical manifestations varied between patients but generally included: gait disturbances, language problems, visual impairment, seizures and psychomotor regression. Cortical and cerebellar atrophy was a constant finding when neuroimaging was performed. Seizure medication was a common element of treatment regimens.
This investigation supports that the previously characterized c.214G > T mutation is the most common causative NCL mutation in the Costa Rican population. This mutation is geographically widespread among Costa Rican NCL patients and yields a clinical presentation similar to that observed for CLN6 NCL patients in other geographies.
神经元蜡样脂褐质沉积症(NCLs)通常被称为 Batten 病,是一组遗传异质性罕见儿科溶酶体贮积症,其特征为细胞内积累 autofluorescent 物质(称为脂褐素)、进行性神经退行性变和神经症状。2002 年,在哥斯达黎加人群中发现 CLN6 基因突变(c.214G>T)可导致该病(致病突变),但这种突变在当地 Batten 病患者中的频率仍不完全明确,对于这一罕见患者群体的临床和人口统计学特征也同样如此。
描述在哥斯达黎加国家儿童医院接受治疗的具有 Batten 病临床诊断的患者的主要社会人口统计学和临床特征,并通过分子检测对其致病突变进行特征描述。
从口腔拭子中提取 DNA,用于 CLN6 基因测序。还从患者的病历中获取参与者的社会人口统计学和临床特征。
确定了 9 例具有 Batten 病临床诊断的患者。基因测序确定 9 例中的 8 例存在先前描述的哥斯达黎加纯合突变。1 例患者的 CLN6 基因无突变。在所有存在哥斯达黎加 CLN6 突变的情况下,均伴有 2 号内含子的替换。患者出生于哥斯达黎加的 7 个省中的 4 个,平均发病年龄接近 4 岁。系谱中无父母近亲结婚。初始临床表现因患者而异,但通常包括:步态障碍、语言问题、视力障碍、癫痫发作和精神运动倒退。当进行神经影像学检查时,皮质和小脑萎缩是一个常见的发现。抗癫痫药物是治疗方案中的常见药物。
本研究支持先前描述的 c.214G>T 突变是哥斯达黎加人群中最常见的 NCL 致病突变。该突变在哥斯达黎加的 NCL 患者中广泛分布,其临床表现与其他地区的 CLN6 NCL 患者相似。